Peiris-Pagès Maria, Bonuccelli Gloria, Sotgia Federica, Lisanti Michael P
Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK.
The Paterson Institute, University of Manchester, Withington, UK.
Oncotarget. 2018 Jan 19;9(17):13254-13275. doi: 10.18632/oncotarget.24285. eCollection 2018 Mar 2.
Mitochondria are dynamic organelles frequently undergoing fission and fusion events to maintain their integrity, bioenergetics and spatial distribution, which is fundamental to the processes of cell survival. Disruption in mitochondrial dynamics plays a role in cancer. Therefore, proteins involved in regulating mitochondrial dynamics are potential targets for treatment. mDIVI1 is an inhibitor of the mitochondrial fission protein DRP1, which induces i) mitochondrial oxidative stress and ii) effectively reduces mitochondrial metabolism. We show here that mDIVI1 is able to inhibit 3D tumorsphere forming capacity, cell migration and stemness-related signalling in breast cancer cells, indicating that mDIVI1 can potentially be used for the therapeutic elimination of cancer stem cells (CSCs).
线粒体是动态细胞器,经常经历分裂和融合事件以维持其完整性、生物能量学和空间分布,这对细胞存活过程至关重要。线粒体动力学的破坏在癌症中起作用。因此,参与调节线粒体动力学的蛋白质是潜在的治疗靶点。mDIVI1是线粒体分裂蛋白DRP1的抑制剂,它会诱导:i)线粒体氧化应激,以及ii)有效降低线粒体代谢。我们在此表明,mDIVI1能够抑制乳腺癌细胞的三维肿瘤球形成能力、细胞迁移和与干性相关的信号传导,这表明mDIVI1可能可用于治疗性消除癌症干细胞(CSCs)。